Malathi Kandarpa

TL;DR: This study demonstrates, for the first time to the authors' knowledge, profound activity of the menin-MLL1 inhibitor as a single agent in clinically relevant PDX models of leukemia and provides a strong rationale for clinical translation of MI-3454 or its analogs for leukemia patients with MLL1 rearrangements or NPM1 mutations.

TL;DR: It is found that small-molecule Usp9x/Usp24 inhibitors may have therapeutic activity in myeloma and improved the drug-like properties of WP1130, and Usp24 protein overexpression was improved.

TL;DR: Perifosine–lenalidomide–dexamethasone was well tolerated and demonstrated encouraging clinical activity in relapsed and relapsed/refractory MM.

TL;DR: It is reported that Ets-1 destruction is regulated by the deubiquitinating enzyme, Usp9x, and has major impact on the tumorigenic program of metastatic melanoma.

TL;DR: These findings provide novel mechanistic rationale behind the potent cell death induced by combining selinexor with carfilzomib and support their use in the treatment of relapsed/refractory myeloma and potentially other cancers.